Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Infliximab in Autoimmune Eyes With Keratoprosthesis
NCT02126020Phase 2Withdrawn
- Start
- Nov 2014
- Primary completion
- Apr 2017
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of infliximab in Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), mucous membrane pemphigoid (MMP). Planned start Nov 2014; status: withdrawn.
02
Drugs
infliximab
03
Conditions
Stevens-Johnson syndrome (SJS)toxic epidermal necrolysis (TEN)mucous membrane pemphigoid (MMP)
Beyond the preview
Go deeper on NCT02126020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02126020.